NCT02121665

Efficacy of a Probiotic Lozenges in Chronic Periodontitis Patients.

Effect of Probiotic Lozenges as an Adjunct to Non Surgical Periodontal Therapy in Chronic Periodontitis Patients: A Randomized Double Blind Placebo Controlled Clinical and Biochemical Study.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: CD Pharma India Pvt. Ltd. · Industry
• Sex: All
• Age: 25 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Periodontal disease is an infectious disease resulting in inflammation within supporting tissues of the teeth, progressive attachment loss, and bone loss. Epidemiological studies reveal that about 10% of the adult population suffer from severe periodontitis.It comprises of two distinct but interconnected etiologic components: the periodontopathic bacteria adjacent to the periodontal tissues, and the host-mediated connective tissue-destructive responses to the causative bacteria and their metabolic products. In the arena of periodontics, the probiotics pose a great potential of plaque modification, halitosis management, altering anaerobic bacteria colonization, improvement of pocket depth, and clinical attachment gain. Aim of the study is to analyze the beneficial effect of probiotic lozenges as an adjunct to Scaling and Root Planing, on clinical and biochemical parameters.

Conditions

• Chronic Periodontitis

Interventions

Type	Name	Description
DRUG	Probiotic (Inersan)	Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
DRUG	Placebo	Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)

Timeline

• Start date: 2014-07-01
• Primary completion: 2016-01-01
• Completion: 2016-03-01
• First posted: 2014-04-23
• Last updated: 2016-07-27

Locations

1 site across 1 country: India